In the search for a preventative treatment of skin cancers, including melanoma, it is imperative to understand and treat DNA damage caused by ultraviolet (UV) radiation. Following the treatment of a ...

CLINUVEL’s DNA Repair Program aims to confirm that intervention with SCENESSE® causes elimination of DNA damage (photoproducts) and regeneration of DNA. The diagram shows that SCENESSE® has been ...

European regulators to evaluate new drug’s safety and efficacy for ‘orphan’ disease erythropoietic protoporphyria (EPP) SCENESSE®, which received an orphan drug designation for EPP in 2008, will be ...

Structural changes in preparation for commercial phase Rotation of Chairman and establishment of Commercial Management Committee Melbourne, Australia - Clinuvel Pharmaceuticals Limited (ASX: CUV; ...

Australian biotech Clinuvel has claimed a US approval for Scenesse, a treatment for a rare skin disorder that causes extreme sensitivity to light. The under-the-skin implant has been cleared by the ...

* Clinuvel pharmaceuticals says ‍European post-marketing safety data to be submitted as part of new drug application, expected in december 2017 * Seeking approval from FDA to market Scenesse in us * ...

Victor A. Mejias had been taking a drug to treat a rare skin disease for about two years when its manufacturer effectively cut off his supply. Mejias was switching dermatologists and needed to find ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE ® ...

Successful first year of drug supply to erythropoietic protoporphyria (EPP) patients under AIFA 648/96 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it ...

Shares of an Australian drugmaker skyrocketed Wednesday morning following the Food and Drug Administration’s approval of its drug to treat a rare condition that causes hypersensitivity to light.

Note to editors: CLINUVEL is releasing in-depth infographics and a video explaining the mechanisms of action in XP and the overall DNA repair process. For updates, follow:Twitter | Facebook | ...